Scientists discover two unique subtypes of a prominent mutation in patients with AML
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with
ABSTRACT
PURPOSE
Patients with myelodysplastic syndrome (MDS) are at risk of relapse after allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict and the impact of conditioning intensity to prevent MDS relapse are unknown.
This article was originally published here
Ann Hematol. 2021 Feb 23. doi: 10.1007/s00277-021-04464-5. Online ahead of print.
ABSTRACT
Abstract
Background
We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period.
Abstract
Background
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also cause lifelong complications.